Clinical and experimental evidence consistently indicates that reduced METTL3 expression is associated with increased disease severity in Th2-dominant asthma, highlighting the potential of m6A-dependent METTL3 activity as a therapeutic target for allergic airway inflammation. Here, METTL3 is linked to asthma.